PLD 117
Alternative Names: PL 9013Latest Information Update: 16 Aug 2007
Price :
$50 *
At a glance
- Originator Receptron
- Class
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 04 Jun 2004 This compound is still in active development
- 25 Nov 2003 Phase I trials have been completed in Thrombocytopenia
- 31 Dec 2000 Phase-I clinical trials for Thrombocytopenia in USA (Unknown route)